RedHill Biopharma Adds Board Members
This article was originally published in Scrip
Executive Summary
Tel-Aviv, Israel-based RedHill Biopharma Ltd. has named Dr. June S. Almenoff and Theresa M. Stevens to its advisory board. Almenoff was recently president, principal executive officer and chief medical officer of Furiex Pharmaceuticals. During her four year tenure, the company's valuation increased approximately 10-fold, culminating in its acquisition by Forest Labs/Actavis plc for approximately $1.2bn in 2014. Stevens was previously chief corporate development officer and senior vice president at Aptalis Pharma (now Actavis plc), leading the company's global M&A, strategy and business development operations.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.